Julie Rubinstein is the President of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Since 2011, she has held a variety of leadership roles and currently oversees Life Sciences Research, Clinical Diagnostics, Drug Discovery, Corporate Marketing and Business Development functions. Ms. Rubinstein was part of the executive team that took the company public in 2019.
Prior to joining Adaptive, Ms. Rubinstein held various worldwide commercial development roles at Pfizer Oncology, primarily focusing on cancer immunotherapy. She also held multiple positions at Johnson & Johnson’s Ethicon Endo-Surgery division, where she helped commercialize a breast cancer diagnostic device in major European markets. She began her career in Morgan Stanley’s Global Health Care Group as a financial analyst. She currently serves on the Board of Trustees for The Valerie Fund, a pediatric oncology organization in New Jersey and New York. Ms. Rubinstein holds a dual degree, summa cum laude and Phi Beta Kappa, from the University of Pennsylvania’s Undergraduate Wharton School and Annenberg School of Communications, with a minor in French. She also holds an MBA from Harvard Business School.